TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug aims to halt deadly Heart-Stiffening disease
Disease control OngoingThis study is testing whether the drug patisiran can help people with ATTR amyloidosis, a condition where abnormal proteins build up and stiffen the heart muscle. It involves 360 participants who have heart failure symptoms from this disease. Researchers will measure if the drug …
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Apr 02, 2026 09:12 UTC
-
Heart disease drug gets extended testing in 700 patients
Disease control ENROLLING_BY_INVITATIONThis study continues testing vutrisiran, an investigational drug for hereditary heart amyloidosis, in patients who previously participated in related trials. Researchers want to understand the long-term safety and effectiveness of continued treatment. The study measures heart fun…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Experimental drug aims to protect hearts from deadly protein buildup
Disease control OngoingThis study is testing whether an investigational drug called vutrisiran can help people with a serious heart condition called ATTR amyloidosis with cardiomyopathy. The drug is given as an injection under the skin every three months. Researchers are comparing it to a placebo to se…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
One-Shot gene therapy aims to halt deadly heart disease
Disease control OngoingThis large, late-stage study is testing whether a single dose of an experimental gene therapy, called NTLA-2001, can help people with a serious inherited heart condition called ATTR-CM. The main goal is to see if the treatment reduces heart-related deaths and hospital visits comp…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC